GSK3 beta, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10284184" target="_blank" >RIV/00216208:11110/14:10284184 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/14:10284184

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.pnpbp.2013.12.001" target="_blank" >http://dx.doi.org/10.1016/j.pnpbp.2013.12.001</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.pnpbp.2013.12.001" target="_blank" >10.1016/j.pnpbp.2013.12.001</a>

Jazyk výsledku

angličtina

Název v původním jazyce

GSK3 beta, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression

Popis výsledku v původním jazyce

Background: Glycogen synthase kinase-3 beta (GSK3 beta), cAMP-response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) play critical roles in neuronal survival, synaptic plasticity and memory and participate in the pathophysiology of both depressive disorder and Alzheimer's disease (AD). Methods: This study was designed to determine the association of GSK3 beta activity, CREB activity and BDNF concentration in peripheral blood of patients with AD with or without depressive symptoms and in depressive patients without AD. GSK3 beta activity in platelets, CREB activity in lymphocytes and BDNF concentration in plasma, platelet-rich plasma or platelets were measured in 85 AD patients (36 of whom displayed co-morbid depressive symptoms), 65 non-AD patients with depressive disorder and 96 healthy controls. AD patients were clinically assessed for stage of dementia, cognitive impairment and severity of depressive symptoms. Depressive patients were clinically assesse

Název v anglickém jazyce

GSK3 beta, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression

Popis výsledku anglicky

Background: Glycogen synthase kinase-3 beta (GSK3 beta), cAMP-response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) play critical roles in neuronal survival, synaptic plasticity and memory and participate in the pathophysiology of both depressive disorder and Alzheimer's disease (AD). Methods: This study was designed to determine the association of GSK3 beta activity, CREB activity and BDNF concentration in peripheral blood of patients with AD with or without depressive symptoms and in depressive patients without AD. GSK3 beta activity in platelets, CREB activity in lymphocytes and BDNF concentration in plasma, platelet-rich plasma or platelets were measured in 85 AD patients (36 of whom displayed co-morbid depressive symptoms), 65 non-AD patients with depressive disorder and 96 healthy controls. AD patients were clinically assessed for stage of dementia, cognitive impairment and severity of depressive symptoms. Depressive patients were clinically assesse

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Progress in Neuro-Psychopharmacology and Biological Psychiatry

ISSN

0278-5846

e-ISSN

—

Svazek periodika

50

Číslo periodika v rámci svazku

April

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

11

Strana od-do

83-93

Kód UT WoS článku

000330574000010

EID výsledku v databázi Scopus

—